MedTrace Logo

Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations

NCT00633074 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2018-06-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to show the non-inferiority of different formulations of GlaxoSmithKline Biologicials' influenza vaccine.

Conditions

Interventions

BIOLOGICAL

Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)

Intramuscular administration, 1 dose

BIOLOGICAL

Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)

Intramuscular administration, 1 dose

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-03
Primary Completion
2008-04-11
Completion
2008-04-11

Countries

  • Estonia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00633074 on ClinicalTrials.gov